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Except for one case, spearman’s rank correlation coefﬁcient
between instruments was high (rho > 0.70). Furthermore, test-
retest reliability in terms of ICC(3,1) was good for all instru-
ments, i.e., 0.98 (95% CI, 0.82–0.99) for the BMJ check-list,
0.96 (95% CI, 0.75–0.99) for the CHEC list, and 0.95 (95% CI,
0.75–0.99) for the QHES instrument. Yet, they were poor agree-
ment between the two examiners (kappa < 0.40 for most items
and ICC(2,1) < 0.5). CONCLUSION: Findings highlight the
subjective character of the assessment. Results are not inﬂuenced
by the instrument used but more by the assessor. It is thus
essential to perform quality analysis of economic evaluations by
at least two experts and to base the ﬁnal scoring on a consensus.
PODIUM SESSION I: PATIENT REPORTED
OUTCOMES I
PR1
RECOMPUTINGVALUES FOR EQ-5D IN ACCORDANCE WITH
NICE APPRAISAL GUIDANCE
Kind P
University of York,York, UK
OBJECTIVES: Measuring the QALY beneﬁts of new health inter-
ventions is critically dependent on the values of the quality-
adjustment index—putting the “Q” in QALYs. For many health-
related quality of life indexes, including EQ-5D, there aremultiple
options when selecting the value set for use in a given application.
For the purposes of health technology assessment in England and
Wales the National Institute for Health and Clinical Excellence
has published guidance thatwhen conducting the appraisal of new
health technologies the values of the relevant population should be
applied. However, the standard set of values used to derive the
EQ-5Dindex were collected from a national UK population survey
that included Scottish respondents whose health care system is
organised and funded separately from the NHS in England and
Wales. This paper reworks the original UK survey data and
presents a new set of weights for EQ-5D recalibrated using the
appropriate population values. METHODS: The Measurement
and Valuation of Health (MVH) survey methods have been fully
described elsewhere. A total of 3395 individuals used ranking,
rating and TTO methods to value a subset of 15 EQ-5D health
states. A total of 360 of these respondents were citizens of
Scotland. RESULTS: Scottish respondents reported similar health
status compared to their English counterparts. However Scottish
TTO values were systematically higher for 23/26 mild-moderate
states and 16/17 states worse than dead were lower than English
values. The Scottish data were removed from the MVH dataset
and a new OLS regression model was constructed (r2 = 0.492).
70% of values for EQ-5D health states in the revised model differ
by more than 0.05 when compared with the original MVH values
currently applied by NICE. The impact of applying these weights
varies with the severity of the condition under review. CONCLU-
SION: The use of existing MVH weights appears contraindicated
if English QALYs are required.
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NON-PERSISTENT USE OF ORAL ANTIDIABETIC DRUGS
LEADSTO 20% DECREASED CHANCE OF HBA1C
GOAL-ATTAINMENT IN DAILY CLINICAL PRACTICE
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OBJECTIVES: Within the Dutch guidelines for treatment of
Type 2 Diabetes Mellitus (T2DM), the target-value of HbA1c has
been set at <7%. The aim of this study was to investigate the
relationship between persistence with oral antidiabetic drug
(OAD-)treatment and HbA1c goal-attainment in daily clinical
practice. METHODS: From the PHARMO record linkage
system, comprising among others, linked drug-dispensing,
clinical laboratory, and hospital data for >2.3 million subjects
in The Netherlands, new users of OADs were identiﬁed in
the period 1999–2005. Patients who started on monotherapy
with metformin, a sulphonylurea (SU), or a thiazolidinedione
(TZD), or on combination therapy with metformin+SU, or
metformin+TZD, with baseline HbA1c °Ý7% and at least one
HbA1c-measurement in the period of 6–12 months after
treatment-onset, were included in the study-cohort. Persistence
with OAD-treatment in the ﬁrst year of treatment was determined
using the method of Catalan, and was deﬁned as the duration of
the ﬁrst treatment-episode in days. In case the ﬁrst treatment-
episode overlapped with the date of a HbA1c-measurement, a
patient was considered persistent at that measurement. Patients
with HbA1c <7% were deﬁned at goal. RESULTS: The study
cohort included 2023 patients. Three-quarters (1512 patients)
were persistent with any OAD at the time of ﬁrst HbA1c-
measurement in the time-period of 6–12 months after OAD-start:
of these, 861 (57%) were at goal. Of the 511 patients who were
non-persistent with any OAD at that time, 239 (47%) were at
goal. Non-persistent patients were about 20% less likely to be at
goal (RR-adj: 0.82; 95% CI: 0.74–0.91), compared to persistent
users of any OAD. CONCLUSION: Non-persistent use of OADs
leads to a 20% decreased chance of HbA1c goal-attainment in
daily clinical practice. This effect of non-persistence seems
modest, but represents a very large number of patients, in whom
OAD-use might be better controlled.
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OBJECTIVES: Compare the risk-beneﬁt preferences of patients,
parents of juvenile patients and gastroenterologists for Crohn’s
disease (CD) treatments. METHODS: Panels of CD patients,
parents of juvenile patients and gastroenterologists completed a
series of choice-format conjoint trade-off tasks with varying
efﬁcacy and risk levels. Parents evaluated treatments for their
child, gastroenterologists evaluated treatments for three patients
(young, middle-aged, elderly). Treatment attributes included
daily symptom severity and activity limitations, potential for CD
complications, time between ﬂare-ups, systemic steroid use, and
three SAE mortality risks: serious infection (SI), progressive mul-
tifocal leukoencephalopathy (PML) and lymphoma. Preference
estimates were used to calculate the annual SAE-speciﬁc
maximum acceptable risk (MAR) for various levels of clinical
beneﬁt. RESULTS: 342 patients, 105 parents of juvenile patients,
and 315 gastroenterologists provided usable data for analysis.
For all respondent groups improvement in daily symptom severity
was the most important factor in treatment preferences and risk
tolerance was greater for treatments with better clinical beneﬁts.
Physicians had lower MARs for young patients and higher MARs
for the elderly. For middle-aged patients, gastroenterologists’
MAR ranged from 0.16% to 0.76% for death or disability from
PML, 0.24% to 0.58% for death from SI, and 0.13% to 0.81%
for death due to lymphoma. Patients’ preferences are similar to
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that of physicians’ preferences for middle-aged patients across
most beneﬁt levels. Compared to adult patients, parents have
greater risk tolerance for treating severe CD symptoms, and
smaller risk tolerance for treating moderate CD symptoms.CON-
CLUSION: Respondents indicated they are willing to accept
deﬁned mortality risks in exchange for clinical efﬁcacy and that
acceptance is affected by the degree of beneﬁt, the patient’s
characteristics and the nature of the SAE. Understanding risk-
beneﬁt preferences can assist in identifying appropriate treat-
ments and in informing welfare-enhancing regulatory decisions.
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BACK PAIN IN GERMANY:ARETHERE DIFFERENCES
CONCERNING HEALTH-RELATED QUALITY OF LIFE (HRQOL)
IN PATIENTSTREATED ACCORDINGTO GUIDELINES,
GUIDELINE INDEPENDENT AND PATIENT SELF-TREATMENT?
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OBJECTIVES: Back pain has a considerable impact on HRQoL,
even with new medications, treatments and guidelines the degree
of suffering for patients is high. The objective was to compare
HRQoL for patients with back pain in Germany for three
different treatment groups (guideline-, non-guideline- and self-
treatment-group). METHODS: Patients were consecutively
recruited by physicians in general practice (n = 54) in 2005.
Patients were categorized into the three groups according to
pre-speciﬁed algorithms. All groups completed the generic SF-36,
and the disease speciﬁc FFbH, von Korff Index and PHQ-D
questionnaires. In addition, a retrospective chart review was
conducted. HRQoL data was compared between the groups.
RESULTS: A total of 145 patients took part in this study
(n = 29 guideline-group, 44 non-guideline-group, 72 with self-
treatment). Patients in the self-treatment-group were younger
than patients in guideline- or non-guideline-group (49.8 vs. 59.4
vs 57. 4 years, p = 0.0021). The groups did not differ signiﬁcantly
in gender or other socio-demographic characteristics. The von
Korff Index was lowest (i.e. poorer) in the self-treatment-group
and highest in the guideline-group (p = 0.0077). Regarding
SF-36, patients in the guideline-group had the lowest physical
(30.2  8.5) and mental (41.2  13.5) component scores, only
the differences regarding physical component were statistically
signiﬁcant between the groups (p < 0.0001), those regarding
mental component were not (p = 0.2875). Regarding PHQ-D
items, the groups did not differ in frequency of major depressive
and other depressive symptoms. The guideline-group had signiﬁ-
cantly higher burden of somatoform symptoms compared to the
other two groups (p = 0.0219). The self-treatment-group had the
highest FFbH-R total score (67.7  21.5) compared to other two
groups (p = 0.0056). CONCLUSION: From the here collected
data, it seems that patients who are treated according to guide-
lines have reached a higher degree of suffering (poorer HRQoL)
compared to those patients with either treated without guidelines
and/or treat themselves. Further research is warranted to conﬁrm
our ﬁndings.
PODIUM SESSION II: CANCER
CN1
USINGTHE FACT-NEUROTOXICITYTO EVALUATE QUALITY
OF LIFE IN CANCER PATIENTS FROM ACROSSTHE GLOBE
Eremenco S, Du H,Arnold B, Herzberg T, Cella D
Evanston Northwestern Healthcare, Evanston, IL, USA
OBJECTIVES: Translation of PRO measures is an essential com-
ponent of research methodology in preparation for multinational
clinical trials. The FACT-Neurotoxicity (FACT-Ntx) is used to
evaluate the quality of life of cancer patients suffering from
neurotoxicity, a side effect of certain treatments. This study set
out to linguistically validate the FACT-Ntx for use in Denmark,
India, Lithuania and South Africa. METHODS: The study
sample consisted of 176 patients (96 males and 80 females), with
varying cancer diagnoses and a mean age of 51 years, speaking
11 languages: Afrikaans (15), Danish (25), Gujarati (15), Hindi
(15), Kannada (15), Lithuanian (15), Malayalam (15), Marathi
(15), Punjabi (15), Tamil (15) and Telugu (16). The FACT-Ntx
was translated according to standard FACIT methodology.
Patients diagnosed with any stage cancer on any treatment and
experiencing neurotoxicity completed the respective translated
version and then participated in cognitive debrieﬁng interviews.
Statistical analyses (descriptive statistics, one-way ANOVA and
reliability analyses) were performed on the quantitative data.
Participant comments were analyzed qualitatively. RESULTS:
The FACT-Ntx translations showed good reliability and linguis-
tic validity. The internal consistency of all languages combined
was 0.86, and all items correlated at an acceptable level. In
general, the Ntx score differed across self-reported Performance
Status Rating (PSR) groups (nonparametric Kruskal-Wallis test
p < 0.0001). A nonparametric Generalized Linear Model (GLM)
approach (with multiple comparison adjusted signiﬁcance level
0.017) showed a difference between ‘PSR = 0’ and ‘PSR = 1’
(p = 0.0002) and a difference between ‘PSR = 0’ and ‘PSR = 2’
(p < 0.0001), both with ‘PSR = 0’ patients reporting less neuro-
toxicity. CONCLUSION: The FACT-Ntx has shown acceptable
reliability and linguistic validity in 11 languages. The instrument
has also shown adequate sensitivity in differentiating patients
with no symptoms and normal activity from patients reporting
some symptoms. We consider these translations acceptable for
use in international research and clinical trials.
CN2
DEVELOPMENT ANDVALIDATION OF OPTIMALLY WEIGHTED
MEASURES OF GLOBAL HEALTH-RELATED QUALITY OF
LIFE (QOL) AND UTILITY BASED ON A CANCER-SPECIFIC
QOL INSTRUMENT
Grimison PS, Simes RJ, Stockler MR
NHMRC Clincial Trials Centre, University of Sydney, Camperdown,
NSW, Australia
OBJECTIVES: To facilitate the comparison of net beneﬁts of
cancer treatments in clinical trials by developing and validating
a system to convert data from a QoL instrument into precise
and optimally weighted global QoL measures and utilities.
METHODS: Two-hundred cancer patients completed the Utility-
Based Questionnaire-Cancer (UBQ-C), a validated 34-item
cancer-speciﬁc instrument which includes scales of health status,
overall QoL, disabilities and distresses. Patients were interviewed
to elicit time trade-off (TTO) utilities for their own health states.
A global QoL measure was derived from a weighted combination
of the UBQ-C scales based on linear regression of health status
on the individual scales. An equation to convert global QoL into
utility was derived. Validity was examined using baseline data
from a RCT of advanced breast cancer chemotherapy (n = 290).
RESULTS: The weighted global QoL measure was more precise
than the single-item QoL scales. Median scores (IQR) were much
lower for the weighted global QoL measure: 0.77 (0.65, 0.85)
than for the direct TTO utility: 0.98 (0.85, 1.0). The best model
to predict utility from weighted global QoL was a power
transformation: TTO = 1-(1-global QoL)2.1. The measures dis-
criminated between RCT subjects with good and poor per-
formance status: mean (95% CI) derived utility scores for
ECOG 0-1 = 0.91 (0.89, 0.92), ECOG 2-3 = 0.75 (0.68, 0.81),
A226 Abstracts
